

# CITATION REPORT

List of articles citing

Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers

DOI: 10.1002/pros.2990260503  
Prostate, 1995, 26, 235-46.

**Source:** <https://exaly.com/paper-pdf/25944399/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
31	New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy. <i>Urologic Clinics of North America</i> , <b>1996</b> , 23, 685-96	2.9	4
30	Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. <i>British Journal of Cancer</i> , <b>1996</b> , 74, 910-6	8.7	109
29	Modulation of experimental systemic lupus erythematosus with linomide. <i>Lupus</i> , <b>1996</b> , 5, 328-33	2.6	3
28	Prostate cancer: where are we and where are we going?. <i>British Journal of Urology</i> , <b>1997</b> , 79 Suppl 1, 2-7		12
27	Advances in angiogenesis research: relevance to urological oncology. <i>Journal of Urology</i> , <b>1997</b> , 158, 1663-74	3.4	77
26	Anti-Angiogenic Treatment with Linomide as Adjuvant to Surgical Castration in Experimental Prostate Cancer. <i>Journal of Urology</i> , <b>1997</b> , 158, 902-907	2.5	25
25	Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. <i>European Journal of Cancer</i> , <b>1997</b> , 33, 566-74	7.5	79
24	Vasorelaxant effects induced by the antiangiogenic drug linomide in aortic and saphenous vein preparations of the rabbit. <i>British Journal of Pharmacology</i> , <b>1997</b> , 122, 1739-45	8.6	2
23	An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. <i>Investigational New Drugs</i> , <b>1997</b> , 15, 49-59	4.3	37
22	Linomide enhances apoptosis in CD4+CD8+ thymocytes. <i>Scandinavian Journal of Immunology</i> , <b>1997</b> , 46, 488-94	3.4	12
21	Angiogenic factors expressed by human prostatic cell lines: effect on endothelial cell growth in vitro. <i>Prostate</i> , <b>1997</b> , 33, 123-32	4.2	13
20	Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells. <i>The Anatomical Record</i> , <b>1997</b> , 249, 63-73		19
19	Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. <i>Prostate</i> , <b>1998</b> , 35, 1-10	4.2	179
18	Reduction in basic fibroblast growth factor mediated angiogenesis in vivo by linomide. <i>Connective Tissue Research</i> , <b>1998</b> , 37, 61-8	3.3	4
17	Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 1648-53	9.7	97
16	The inhibitory effect in experimental autoimmune encephalomyelitis by the immunomodulatory drug Linomide (PNU-212616) is not mediated via release of endogenous glucocorticoids. <i>Autoimmunity</i> , <b>1998</b> , 28, 235-41	3	10
15	Chapter 3 Animal model systems for the study of prostate cancer. <i>Advances in Oncobiology</i> , <b>1999</b> , 3, 33-46		

14	Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages. <i>Autoimmunity</i> , <b>2000</b> , 32, 199-211	3	18
13	Role of angiogenesis in the progression and treatment of prostate cancer. <i>Cancer Investigation</i> , <b>2001</b> , 19, 181-91	2.1	26
12	Structure-activity relationships studies of the anti-angiogenic activities of linomide. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2003</b> , 13, 1187-9	2.9	32
11	Linomide inhibits insulinitis and modulates cytokine production in pancreatic islets in the nonobese diabetic mouse. <i>International Immunopharmacology</i> , <b>2003</b> , 3, 17-30	5.8	3
10	Human prostate cancer risk factors. <i>Cancer</i> , <b>2004</b> , 101, 2371-490	6.4	409
9	Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. <i>Prostate</i> , <b>2006</b> , 66, 1768-78	4.2	70
8	The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. <i>Prostate</i> , <b>2007</b> , 67, 790-7	4.2	52
7	The role of angiogenesis inhibitors in prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2008</b> , 14, 20-5	2.2	27
6	Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. <i>Molecular Cancer</i> , <b>2010</b> , 9, 107	42.1	69
5	N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3K $\beta$ ). <i>Bioorganic and Medicinal Chemistry</i> , <b>2012</b> , 20, 7175-83	3.4	21
4	Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). <i>Prostate</i> , <b>2012</b> , 72, 913-24	4.2	39
3	A review of tasquinimod in the treatment of advanced prostate cancer. <i>Drug Design, Development and Therapy</i> , <b>2013</b> , 7, 167-74	4.4	9
2	Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. <i>OncoTargets and Therapy</i> , <b>2014</b> , 7, 223-34	4.4	11
1	Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. <i>Journal of Urology</i> , <b>1997</b> , 158, 902-7	2.5	6